NantHealth Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

NantHealth şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

Geri Alım Getirisi

Toplam Hissedar Getirisi	0%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NEL0 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NEL0 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

NantHealth Piyasaya Karşı Temettü Getirisi

NEL0 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NEL0)	n/a
Pazarın Alt %25'i (DE)	1.8%
Pazarın En İyi %25'i (DE)	4.8%
Sektör Ortalaması (Healthcare Services)	2.6%
Analist tahmini (NEL0) (3 yıla kadar)	n/a

Önemli Temettü: NEL0 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NEL0 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NEL0 şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NEL0 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

NantHealth Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Nanthealth, Inc. Announces Resignation of Deanna L. Wise from Her Position on the Board and as A Member of the Special Committee, the Audit Committee, and the Nominating and Corporate Governance Committee of the Board

Summus Holdings Engages in Discussions with NantHealth

NantHealth, Inc. Announces Executive Changes

Nant Capital Engages in Discussions with NantHealth

Nant Capital Engages in Discussions with NantHealth

NantHealth, Inc. announced delayed 10-Q filing

NantHealth, Inc.(NasdaqGS:NH) dropped from S&P TMI Index

NantHealth Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Publicly Held Shares Requirement

First quarter 2023 earnings released: US$1.59 loss per share (vs US$2.07 loss in 1Q 2022)

NantHealth Receives Written Notice from Nasdaq Stating the Company Has Not Complied with the Public Float Requirement Prior to the Expiration of the Compliance Period

Full year 2022 earnings released: US$8.80 loss per share (vs US$7.66 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.094 loss in 3Q 2021)

NantHealth, Inc. to Report Q3, 2022 Results on Nov 03, 2022

NantHealth, Inc. Receives Written Notice from Nasdaq

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2021)

NantHealth, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.14 loss in 1Q 2021)

NantHealth, Inc. to Report Q1, 2022 Results on May 05, 2022

NantHealth, Inc. Receives Notice from the Nasdaq Stock Market LLC

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

NantHealth, Inc. to Report Q4, 2021 Results on Feb 24, 2022

NantHealth, Inc. Announces Not Stand for Re-Election of Michael S. Sitrick as Member of the Board Directors

Third quarter 2021 earnings released: US$0.094 loss per share (vs US$0.099 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.43 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.081 loss in 1Q 2020)

NantHealth, Inc. Launches Eviti Connect for Autoimmune Diseases

Founder recently bought €4.2m worth of stock

Founder recently bought €4.2m worth of stock

NantHealth, Inc. announced that it expects to receive $137.5 million in funding from Nant Capital, LLC, Highbridge Capital Management, LLC

Chief Operating Officer recently sold €249k worth of stock

Full year 2020 earnings released: US$0.80 loss per share (vs US$0.57 loss in FY 2019)

Revenue misses expectations

NantHealth, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €3.88

NantHealth, Inc. and Sesame Announces Collaboration to Help Providers Increase Productivity and Better Serve Patients

New 90-day high: €3.41

NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemic’s Impact on Cancer Care

NantHealth, Inc. and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports

Revenue beats expectations

Third quarter 2020 earnings released: US$0.099 loss per share

New 90-day low: €1.75

NantHealth, Inc. to Report Q3, 2020 Results on Nov 05, 2020

NantHealth, Inc. to Report Q2, 2019 Results on Aug 08, 2019

NantHealth, Inc. Enhances Interoperability of the Navinet Open Platform with Expanded API Capabilities

NantHealth, Inc. Rolls Out Navinet AllPayer Platform Nationally

New 90-day low - €2.23

First half earnings released

NantHealth, Inc. to Report Q2, 2020 Results on Aug 06, 2020

NantHealth, Inc. (NasdaqGS:NH) acquired The OpenNMS Group, Inc. Cambridge Equities, LP.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin